Clinicopathological factors that may affect the BRAF mutation rate in PTC are age, sex, histologic variants, tumor size, extrathyroidal extension, multifocality, and Hashimoto thyroiditis [31,32]. This evidence concerns the gene BRAF and Hashimoto thyroiditis.